INSILICO Achieves Milestone in Collaboration with TaiGen as CKD Anemia Drug ISM4808 Doses First Patient in Phase I Trial

Stock News03-06 08:06

INSILICO (03696) announced that ISM4808, an innovative drug for chronic kidney disease (CKD) anemia previously out-licensed to TaiGen (Stock Code: 4157.TWO), has achieved the first contractual milestone. Recently, TaiGen successfully completed the enrollment and dosing of the first participant in the Phase I clinical trial for this AI-driven PHD inhibitor. The trial is a randomized, double-blind, placebo-controlled study, including single ascending dose (SAD) and multiple ascending dose (MAD) phases, designed to evaluate the safety, tolerability, and pharmacokinetic profile of ISM4808 in healthy adults. INSILICO entered into a pipeline authorization agreement with TaiGen for the ISM4808 project in December 2025. Under the agreement, TaiGen obtained exclusive rights to develop, commercialize, and sublicense ISM4808 in Greater China, including mainland China, Hong Kong, Macau, and Taiwan. INSILICO will receive an upfront payment, development and sales milestone payments, and tiered royalties based on net sales, with the total transaction value reaching tens of millions of US dollars.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment